Cancer Vaccines, Adjuvants, and Delivery Systems
Vaccination was first pioneered in the 18th century by Edward Jenner and eventually led to the development of the smallpox vaccine and subsequently the eradication of smallpox. The impact of vaccination to prevent infectious diseases has been outstanding with many infections being prevented and a si...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.627932/full |
| _version_ | 1830090392534515712 |
|---|---|
| author | Samantha J. Paston Victoria A. Brentville Peter Symonds Lindy G. Durrant |
| author_facet | Samantha J. Paston Victoria A. Brentville Peter Symonds Lindy G. Durrant |
| author_sort | Samantha J. Paston |
| collection | DOAJ |
| description | Vaccination was first pioneered in the 18th century by Edward Jenner and eventually led to the development of the smallpox vaccine and subsequently the eradication of smallpox. The impact of vaccination to prevent infectious diseases has been outstanding with many infections being prevented and a significant decrease in mortality worldwide. Cancer vaccines aim to clear active disease instead of aiming to prevent disease, the only exception being the recently approved vaccine that prevents cancers caused by the Human Papillomavirus. The development of therapeutic cancer vaccines has been disappointing with many early cancer vaccines that showed promise in preclinical models often failing to translate into efficacy in the clinic. In this review we provide an overview of the current vaccine platforms, adjuvants and delivery systems that are currently being investigated or have been approved. With the advent of immune checkpoint inhibitors, we also review the potential of these to be used with cancer vaccines to improve efficacy and help to overcome the immune suppressive tumor microenvironment. |
| first_indexed | 2024-12-16T17:02:07Z |
| format | Article |
| id | doaj.art-74f5a3c373814ae3a94a70b4e00f3501 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-16T17:02:07Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-74f5a3c373814ae3a94a70b4e00f35012022-12-21T22:23:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-03-011210.3389/fimmu.2021.627932627932Cancer Vaccines, Adjuvants, and Delivery SystemsSamantha J. Paston0Victoria A. Brentville1Peter Symonds2Lindy G. Durrant3Biodiscovery Institute, Scancell Limited, Nottingham, United KingdomBiodiscovery Institute, Scancell Limited, Nottingham, United KingdomBiodiscovery Institute, Scancell Limited, Nottingham, United KingdomBiodiscovery Institute, University of Nottingham, Faculty of Medicine and Health Sciences, Nottingham, United KingdomVaccination was first pioneered in the 18th century by Edward Jenner and eventually led to the development of the smallpox vaccine and subsequently the eradication of smallpox. The impact of vaccination to prevent infectious diseases has been outstanding with many infections being prevented and a significant decrease in mortality worldwide. Cancer vaccines aim to clear active disease instead of aiming to prevent disease, the only exception being the recently approved vaccine that prevents cancers caused by the Human Papillomavirus. The development of therapeutic cancer vaccines has been disappointing with many early cancer vaccines that showed promise in preclinical models often failing to translate into efficacy in the clinic. In this review we provide an overview of the current vaccine platforms, adjuvants and delivery systems that are currently being investigated or have been approved. With the advent of immune checkpoint inhibitors, we also review the potential of these to be used with cancer vaccines to improve efficacy and help to overcome the immune suppressive tumor microenvironment.https://www.frontiersin.org/articles/10.3389/fimmu.2021.627932/fulladjuvantpeptide vaccineDNA vaccinecancervaccine |
| spellingShingle | Samantha J. Paston Victoria A. Brentville Peter Symonds Lindy G. Durrant Cancer Vaccines, Adjuvants, and Delivery Systems Frontiers in Immunology adjuvant peptide vaccine DNA vaccine cancer vaccine |
| title | Cancer Vaccines, Adjuvants, and Delivery Systems |
| title_full | Cancer Vaccines, Adjuvants, and Delivery Systems |
| title_fullStr | Cancer Vaccines, Adjuvants, and Delivery Systems |
| title_full_unstemmed | Cancer Vaccines, Adjuvants, and Delivery Systems |
| title_short | Cancer Vaccines, Adjuvants, and Delivery Systems |
| title_sort | cancer vaccines adjuvants and delivery systems |
| topic | adjuvant peptide vaccine DNA vaccine cancer vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.627932/full |
| work_keys_str_mv | AT samanthajpaston cancervaccinesadjuvantsanddeliverysystems AT victoriaabrentville cancervaccinesadjuvantsanddeliverysystems AT petersymonds cancervaccinesadjuvantsanddeliverysystems AT lindygdurrant cancervaccinesadjuvantsanddeliverysystems |